<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04194268</url>
  </required_header>
  <id_info>
    <org_study_id>RADONK-PACK-2019</org_study_id>
    <nct_id>NCT04194268</nct_id>
  </id_info>
  <brief_title>Pancreatic Cancer and Carbon Ion Radiotherapy</brief_title>
  <acronym>PACK</acronym>
  <official_title>Pancreatic Cancer and Carbon Ion Radiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Heidelberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Heidelberg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Irradiation of non-operable pancreatic cancer with carbon ions (C12). This therapy is
      expected to be more effective than the current Gold Standard of photon irradiation applied in
      the case of non-operable pancreatic cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 3, 2019</start_date>
  <completion_date type="Anticipated">December 3, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 3, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>survival</measure>
    <time_frame>12 month after radiation</time_frame>
    <description>overall survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>toxicity outcomes</measure>
    <time_frame>48 Month after radiatoin</time_frame>
    <description>Incidence of grade 3/4 NCI-CTC-AE toxicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>survival</measure>
    <time_frame>12 month after radiation</time_frame>
    <description>Progression free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Parameters Ca 19-9</measure>
    <time_frame>48 Month after radiation</time_frame>
    <description>Change in Ca 19-9</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Parameters CEA</measure>
    <time_frame>48 Month after radiation</time_frame>
    <description>Change in CEA levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QLQ) EORTC QLQ C30</measure>
    <time_frame>48 Month after radiation</time_frame>
    <description>Change on scoring on EORTC QLQ C30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life EORTC QLQ Pan26</measure>
    <time_frame>48 Month after radiation</time_frame>
    <description>Change on scoring EORTC QLQ Pan26</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Interventional arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carbon Ion Radiation 12 x 4 Gy (RBE) within 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Carbon Ion</intervention_name>
    <description>12 x 4 Gy (RBE)</description>
    <arm_group_label>Interventional arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed, inoperable primary or local recurrent pancreatic cancer

          -  Written informed consent (must be available before enrollment in the trial)

          -  Karnofsky performance score &gt; 60 or ECOG-status 0/1 (at least: patient should be able
             to take care of himself, although daily-life activity or work is not possible)

          -  Age â‰¥ 18 years

        Exclusion Criteria:

          -  No clear difference between tumor edge and upper gastrointestinal tract in baseline
             imaging

          -  Extensive lymphatic metastases

          -  Disability of subject to understand character and individual consequences of the
             clinical trial

          -  Distant metastases

          -  Previous radiotherapy of the upper abdomen

          -  Active medical implants (e.g. pacemaker, defibrillator), contradicting radiotherapy at
             HIT

          -  Participation in another clinical study or observation period of competing trials,
             respectively
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Klaus Herfarth, Prof.</last_name>
    <phone>06221 56</phone>
    <phone_ext>38260</phone_ext>
    <email>klaus.herfarth@med.uni-heidelberg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jakob Liermann, MD PhD</last_name>
    <phone>06221 56</phone>
    <phone_ext>8201</phone_ext>
    <email>Jakob.liermann@med.uni-heidelberg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hopsital Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klaus Herfarth, MD PhD</last_name>
      <phone>+49 6221 56</phone>
      <phone_ext>38260</phone_ext>
      <email>klaus.herfarth@med.uni-heidelberg.de</email>
    </contact>
    <contact_backup>
      <last_name>Jakob Liermann, MD PhD</last_name>
      <phone>+49 6221 56</phone>
      <phone_ext>34699</phone_ext>
      <email>jakob.liermann@med.uni-heidelberg.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>December 9, 2019</study_first_submitted>
  <study_first_submitted_qc>December 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2019</study_first_posted>
  <last_update_submitted>February 25, 2020</last_update_submitted>
  <last_update_submitted_qc>February 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Heidelberg</investigator_affiliation>
    <investigator_full_name>Juergen Debus</investigator_full_name>
    <investigator_title>Head of Department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

